NEW YORK (GenomeWeb) – Private DNA synthesis firm Twist Bioscience said today that it has closed a $61 million Series D round of financing with a group of existing and new investors.

Investors included Arch Overage Fund, Merieux Developpement, Cormorant Asset Management, Fidelity Management and Research Company, and Foresite Capital Management. Other investors included Arch Venture Partners, WuXi Healthcare Ventures, Illumina, Nick and Joby Pritzker, Paladin Capital Group, Yuri Milner, and Boris Nikolic.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.